Byron Donalds
Suspicious Timing Detected
3 flagsRep. Donalds sold $1,001 - $15,000 in $ABT on 2025-12-04, 14 days before the introduction of HR6897, the "Thyroid Disease CARE Act of 2025," which authorizes funding for thyroid disease research.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | \u2014 | Bitcoin(Cryptocurrency) | $50K-$100K | — | — | — | Dec 18, 2025 |
| BUY | $FIX | Comfort Systems USA, Inc. Common Stock | $1K-$15K | — | — | — | Dec 4, 2025 |
| BUY | $FIX | Comfort Systems USA, Inc. Common Stock | $1K-$15K | — | — | — | Dec 4, 2025 |
| SELL | $ABT | Abbott Laboratories Common Stock | $1K-$15K | — | — | — | Dec 4, 2025 |
| SELL | $ABT | Abbott Laboratories Common Stock | $1K-$15K | — | — | — | Dec 4, 2025 |
Connected Legislative Activity
8 signalsThese bills and contracts share tickers or sectors with this filing's trades.
PrEP and PEP are Prevention Act
The PrEP and PEP are Prevention Act mandates no-cost coverage for HIV prevention drugs and related services, directly increasing demand for these medications and associated diagnostic tests. This legislation creates a guaranteed market expansion for pharmaceutical companies producing PrEP/PEP drugs and diagnostic providers, while increasing costs for health insurers.
Thyroid Disease CARE Act of 2025
The Thyroid Disease CARE Act of 2025 authorizes $30 million annually for five years for thyroid disease research, improving diagnostics, and treatment. This directly benefits companies involved in medical diagnostics, research tools, and pharmaceutical development for thyroid conditions. The bill's referral to the House Committee on Energy and Commerce indicates a standard legislative path.
To require the Secretary of State, in consultation with the Secretary of Health and Human Services and other relevant departments and agencies, as appropriate, to formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, and for other purposes.
HR7879, the "SUPER BUGS Act of 2026," introduced on March 9, 2026, directs the Secretary of State to formulate a strategy for international collaboration on pandemic product development. This bill is in its early stages, referred to the House Committee on Foreign Affairs, and does not authorize specific funding, thus having no immediate direct financial impact on companies. However, it signals potential future policy that could benefit pharmaceutical and biotechnology companies by expanding global market access for qualified pandemic or epidemic products.
Dental Care for Veterans Act
The Dental Care for Veterans Act expands VA dental care eligibility to all enrolled veterans, creating a significant new revenue stream for dental service providers and equipment manufacturers. This bill directly increases the total addressable market for dental services and products within the VA system by an estimated $5-10 billion annually. Dental supply companies and healthcare insurers offering dental plans will see increased demand.
Medical Foods and Formulas Access Act of 2025
The Medical Foods and Formulas Access Act of 2025 expands federal health program coverage for medical foods and vitamins for digestive and inherited metabolic disorders, directly increasing market demand for specialized nutritional products. This legislation guarantees payment for products from manufacturers and distributors, driving revenue growth in the medical nutrition sector. The bill has bipartisan support and is referred to the Committee on Finance, indicating a clear path forward.
Ensuring Patient Access to Critical Breakthrough Products Act
The 'Ensuring Patient Access to Critical Breakthrough Products Act' (HR5343) has advanced out of committee, indicating significant legislative momentum for expedited Medicare coverage of FDA-designated breakthrough medical devices. This bill directly benefits manufacturers by removing a key barrier to market adoption and revenue generation. Companies like Medtronic, Intuitive Surgical, Abbott Laboratories, Johnson & Johnson, and Becton, Dickinson and Company are positioned to gain from this accelerated market access.
To amend the Federal Food, Drug, and Cosmetic Act to establish standardized pathogen and microorganism testing of infant formula products and manufacturing facilities, to mandate notification of specific positive tests and inspection classifications, and for other purposes.
HR7867, the "Infant Formula Safety Modernization Act of 2026," mandates stricter pathogen testing and reporting for infant formula manufacturers. This bill, currently in the early stages of referral to committee, increases operational costs and regulatory scrutiny for companies like Abbott Laboratories ($ABT) and The Kraft Heinz Company ($KHC).
Medical Device Nonvisual Accessibility Act of 2025
The Medical Device Nonvisual Accessibility Act of 2025 (HR5605) has been introduced in the House and referred to the Committee on Energy and Commerce. This bill mandates nonvisual accessibility standards for medical devices with digital interfaces, creating new compliance requirements for manufacturers while expanding market access to blind and low-vision consumers. There is no explicit funding amount specified in the bill.
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.